EPO and bipolar disorder: 2017), intranasal insulin (McIntyre et al. 2012) and Withania somnifera (Chengappa et al. 2013) although findings from the W. somnifera study did not survive correction for multiple comparisons. Improvements in cognitive performance in bipolar depression was reported with erythropoietin (Miskowiak et al. 2014), mifepristone (Young et al. 2004; Watson et al. 2012) and creatine monohydrate (Toniolo et al. 2017).